检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:何晓雯[1] 向希映[1] 王群兴[1] 周宜兰[1] 曾一芹[1] 易虹[1] 王娟[1]
机构地区:[1]三峡大学第一临床医学院
出 处:《微循环学杂志》2005年第4期89-90,共2页Chinese Journal of Microcirculation
摘 要:目的探讨本地区解脲脲原体(Uu)感染及耐药情况,指导临床合理用药。方法对临床送检的531份标本进行Uu培养、计数、鉴定和药敏试验;对775份标本进行荧光定量PCR(FQ-PCR)法和培养法检测Uu。结果FQ-PCR法检出Uu阳性339例,阳性率43.74%。培养法检出Uu206例,阳性率38.79%。Uu对9种抗菌药物的耐药率最高为环丙沙星(CIP)80.10%,最低为交沙霉素(JOS)0.00%,敏感率最高为原始霉素(PRI)98.54%。结论Uu用两种方法检测均可有效检出。培养法能提供药敏结果,更有利于临床治疗。药敏结果提示本地区Uu感染经验用药可选择交沙霉素和强力霉素。Objective: To analyze current Ureaplasma urealyticum infection status and its drug-resistance conditions among both urban and sub-urban areas in Yichang; To provide clinical guidelines on administration of antibiotics against diseases caused by Ureaplasma urealyticum infection.Method: The 531 submitted clinical specimens were cultured, enumerated, identificated and antimicrobial sensitivity tested in vitro; 775 submitted specimens were tested by fluorescence qantitative polymerase chain reaction(FQ-PCR).Results: We got 339 Uu (positive rate:43.74%) by FQ-PCR method and 206 Uu (positive rate:38.79%) by cultural method . Among the nine drugs used in our test, ciprofloxacin(CIP) has the highest drug-resistance rate of 80.10% and josamycin(JOS)has the lowest drug-resistance rate of 0.0%. Our tests also showed that pristinamycin(PRI) had the highest drug-susceptivity rate of 98.54% by cultural method.Conclusion: Ureaplasma urealyticum could be identified by both PCR(FQ-PCR) and cultural methods. Cultural method is preferred for clinical practice because it can also provide drug susceptivity results which could be better applied for clinical treatment purpose. Our test showed that josamycin and doxycycline were useful drug.
关 键 词:耐药性分析 解脲脲原体感染 解脲脲原体(Uu) 检测 荧光定量PCR方法 非淋菌性尿道炎 盆腔炎症性疾病 体外 新生儿低体重 泌尿生殖道
分 类 号:R181.34[医药卫生—流行病学] R698.2[医药卫生—公共卫生与预防医学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.145